Fatty Liver: Not How Much Fat, but Whether Scarring Has Already Begun

Most people who come to us with a fatty liver did not come because of it. They had an abdominal ultrasound for some other reason — pain on the right side, a workup for gallstones, a scan bundled into an executive screening (seker menahalim) — and the last line of the report contained a short sentence: mild hepatic steatosis. Whatever followed, if anything followed, was a single instruction: lose a bit of weight. No number, no further test, no date for the next conversation.

That sentence is not wrong. It simply answers a small part of the question. Two things of consequence fall through the gap it leaves, and both can be closed with information already sitting in your file at your health fund (kupat holim). The first is what the finding actually indicates — and the answer has more to do with the heart than with the liver. The second is which question to ask now, and it is not how much fat is in there. It is whether scarring has already begun.

Fatty liver is a metabolic disease that happens to involve the liver

This is the most common chronic liver disease in the developed world, and the estimates in general circulation run from roughly a fifth to about a third of the adult population. A figure of that magnitude no longer describes a rare disease found by accident. It describes the hepatic consequence of a very common metabolic pattern.

The mechanism is straightforward to state. When tissues become less sensitive to insulin, the pancreas compensates by secreting more of it, and the flow of fatty acids and glucose toward the liver rises. The liver makes and stores fat faster than it clears it, and the surplus stays in the cells. Fat in the liver is not the first problem in the chain. It is the visible sign of it. That is why it travels with a widening waist, high triglycerides, low HDL, borderline blood pressure and pre-diabetes, and why it also appears in people whose BMI is entirely normal but whose visceral fat is not.

Which leads to the point that surprises almost every patient who hears it for the first time: the most common cause of death in people with fatty liver is not hepatic but cardiovascular. For the great majority, the liver will never be the organ that determines the course of their life. The arteries will. The practical implication is that this finding does not belong in a separate folder at the gastroenterologist. It belongs beside waist circumference, fasting insulin, triglycerides, ApoB and blood pressure — inside the overall risk assessment rather than alongside it.

What the ultrasound sees, and what it cannot

Ultrasound is a reasonable tool for detecting fat in the liver, but it has two limitations worth knowing before you treat the report as a measurement. First, it is insensitive to mild steatosis: below a certain fat fraction the liver looks normal when it is not, and sensitivity depends on the equipment and on the operator. Second, the grading of mild, moderate or severe is a visual impression rather than a number. It should not be compared between imaging centres, and often not between two scans at the same centre.

The most important limitation, though, is a different one. Standard ultrasound does not stage fibrosis. It says something about how much fat is present, and apart from indirect signs that appear only at a very advanced stage it says nothing about the question that determines prognosis. The same is true of liver enzymes. Normal ALT and AST do not exclude significant disease; a substantial proportion of people with advanced fibrosis carry enzymes within the reference range, and those are precisely the people who are told for years that everything is fine.

The question is not how much fat is visible in the liver. The question is whether scar tissue has already formed. Ultrasound answers the first approximately; the second it does not answer at all.

Fibrosis is the variable that decides

The research of recent years points in a fairly consistent direction: the amount of fat in the liver predicts very little about the future, whereas the stage of fibrosis is the strongest predictor of morbidity and mortality — liver-related and overall. A person with fat and no scarring is in a materially different position from a person with the same quantity of fat and advanced fibrosis, even when the two ultrasound reports read identically.

And the fair qualification, which should be said immediately: the large majority of people with a fatty liver will never develop significant fibrosis. This is not a condition that progresses in everyone, and progression — where it occurs — is usually very slow, measured in years and decades. The purpose of the workup is not to convert a large share of the population into liver patients. It is the exact opposite: to separate, cheaply and quickly, the majority who need no hepatic follow-up whatsoever from the minority who do, and to stop giving both groups the same reassuring line at the end of a page.

FIB-4: the calculation already in your file, with no new test

This is the practical part. Initial risk stratification for fibrosis requires no new investigation. The accepted first-step index is FIB-4, built from four inputs only: age, platelet count, ALT and AST. The last three appear in any routine blood count and chemistry panel, so they are almost certainly in your file already — often from previous years too. The formula is simple: age multiplied by AST, divided by the platelet count multiplied by the square root of ALT. Free calculators exist online, and a physician can work it out in seconds.

Current guidance, American and European alike, places FIB-4 as the first stratification step in anyone who has a fatty liver together with metabolic risk factors — before advanced imaging and before referral. It is also the prevailing approach among hepatologists in Israel.

The index has real limitations and should not be treated as an answer. It is less reliable at very young ages, tends to overestimate in older adults, and is distorted by anything that alters the platelet count for a non-hepatic reason. Against that: it costs nothing, requires no appointment, and ends the workup for most people. Those who land in the indeterminate range or above are exactly the people who should go on to elastography, which measures liver stiffness non-invasively. Its availability and coverage vary between the health funds and between institutions, and it is worth checking in advance.

Why the name was changed to MASLD

Until recently this was called NAFLD — non-alcoholic fatty liver disease. The definition was constructed by exclusion: not alcohol, not viral hepatitis, not a drug. A definition of that kind states what the disease is not rather than what it is, which is why it was replaced. The accepted term today is MASLD, metabolic dysfunction-associated steatotic liver disease, and its criteria are positive and explicit: fat in the liver together with at least one recognised cardiometabolic marker, among them excess weight or an enlarged waist, impaired glucose regulation or diabetes, raised blood pressure, high triglycerides or low HDL.

The change is not merely semantic. It obliges whoever makes the diagnosis to say out loud which metabolic disturbance is present, and it created a separate category for people who drink significant amounts of alcohol while also meeting the metabolic criteria — an acknowledgement that the two contributors add to one another rather than cancelling out. The inflammatory stage, formerly NASH, is now MASH. For the practical reader there is one conclusion: the new name states plainly what the old one concealed, that this is a metabolic disease for which the liver is only the address.

What actually helps, and what does not yet

For the average reader the answer is not a drug. It is not complicated either, but neither is it one sentence at the end of an ultrasound report:

• Weight loss, by dose. The effect depends on the size of the loss: a modest reduction already lowers liver fat, while improving inflammation and certainly fibrosis requires a larger and more sustained one. This is why lose a bit of weight is not a clinical instruction.
• Exercise, even without weight loss. Resistance training and aerobic activity reduce liver fat and improve insulin sensitivity even when the number on the scale does not move.
• Alcohol and sweetened drinks. It is worth telling your physician the real figure rather than the respectable one. Liquid fructose in particular goes straight to the liver.
• Treat the neighbours. Blood pressure, lipids and glucose are what will determine the outcome for most people. It is also worth knowing that statins are not contraindicated in fatty liver — they are considered safe in this population, and are often avoided unnecessarily because of mildly raised enzymes.

As for dedicated drug therapy: recent years have brought the first approvals in the United States for MASH with moderate to advanced fibrosis, one of them from the GLP-1 family. The indication is confined to that stage, and regulatory status and availability differ between countries — what is registered and actually obtainable in Israel is a separate question worth checking. For a person with mild steatosis and a low FIB-4, none of it applies. Anyone presenting such treatment as a general answer to fatty liver is presenting more than exists.

What to do with this before the next appointment

Three actions, all within reach, none of which requires a new referral:

• Open your old results. Find ALT, AST and platelet count — ideally from two or three separate points in time. With your age, that is everything needed to calculate FIB-4.
• Bring one precise question. Not what about my liver, but: what is my FIB-4, and does it justify elastography? That is a question a physician can answer in a minute.
• Ask for the workup to be metabolic rather than hepatic. Fasting insulin alongside glucose, a full lipid profile, waist circumference, blood pressure, and ApoB once. That is what will determine what is genuinely putting you at risk.

Mild hepatic steatosis on an ultrasound report is not a verdict, and it is not meaningless either. It is a sign that the metabolic system has started to speak, and it deserves an answer containing a number, a risk stratum and a date for follow-up — not a reassuring line at the foot of a page. If you would like to see the finding in its proper place, inside a comprehensive assessment that holds both the metabolic and the cardiovascular measures, you can arrange a conversation and find out what makes sense for you.